Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Emgality (galcanezumab-gnlm) is indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
• This summary is based on the review of 23 systematic review(s)/meta-analysis(es). ^[1-23]
• Reduction in Monthly Migraine Days (MMDs): Galcanezumab significantly reduced MMDs, with reductions of 1.98 days (120 mg) and 1.86 days (240 mg) compared to placebo. It showed comparable or superior effectiveness to other anti-CGRP antibodies.
• Responder Rate (≥50% Reduction in Migraine Days): Galcanezumab achieved a 54% responder rate for reducing migraine days by at least 50%, similar to other anti-CGRP antibodies.
• Transition from Medication Overuse (MO) or Medication Overuse Headache (MOH): Galcanezumab was statistically significant in transitioning patients from MO or MOH to non-MO status, with a relative risk (RR) of 1.44, compared to a higher RR of 1.71 in the Tripan group.
• Effectiveness in Episodic and Chronic Migraine: Galcanezumab was effective in reducing monthly migraine days and headache days in both episodic and chronic migraine, with similar effectiveness to other anti-CGRP antibodies.
• Adverse Events (AEs): Galcanezumab was associated with mild to moderate AEs, including injection-site pain and nasopharyngitis, with a safety profile similar to placebo and comparable to other anti-CGRP antibodies like erenumab and fremanezumab.
• Serious Adverse Events (SAEs): Galcanezumab did not significantly increase the incidence of SAEs compared to placebo, with similar observations noted for other anti-CGRP antibodies.
• Treatment-Emergent Adverse Events (TEAEs): Galcanezumab showed higher odds of TEAEs (OR 1.63) compared to placebo; however, eptinezumab 30 mg had the lowest odds, and atogepant 120 mg had the highest odds of TEAEs among the compared treatments.
• There is no population types or subgroups information available in the reviewed studies.